Rol actual de la quimioterapia en cáncer de urotelio tras fracaso a platinos

28 / 66

2nd line Ramucirumab/Docetaxel
Petrylak D et al. The Lancet 2017
Locally advanced,
unresectable or
mets UC
Progression <14
mo after platinum
regimen
Prior immune CP
allowed
PS 0-1
R
A
N
D
O
M
I
Z
E
Ramucirumab 10 mg/kg + docetaxel 75 mg/m2
D1 of a 21 day cycle
Placebo + Docetaxel 75 mg/m2
D1 of a 21 day cycle
1:1
Primary endpoint: PFS
Secondary: OS, ORR, DCR, safety, PROs
N=530